How do you approach prophylaxis against glucocorticoid-induced osteoporosis in patients with end-stage renal disease on dialysis?

Topics: Rheumatology • Osteoporosis • Hemodialysis • Chronic kidney disease • Nephrology • GIOP • Endocrinology

Answer from: at Academic Institution

Treating patients with end-stage renal disease on glucocorticoids to prevent bone loss is a challenge. A patient with end-stage renal disease cannot be treated with bisphosphonates. However, denosumab the RANKL antibody has no restrictions regarding renal disease. So my suggestion is to treat a pati...

Comments

at Optum
Is there a limit on the length of time that we cou...

at UC Davis
Interestingly, there is no limit to the length of ...

at Norton Rheumatology Specialists
The package insert for denosumab states that it sh...

at Tristate Arthritis & Rheumatology
What anti-resorptive therapy would be recommended ...

at PIH Health
How do you differentiate this population of ESRD p...

Related Questions